A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Briciclib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 30 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 30 May 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.